New antidote for smoke-related cyanide toxicity shows promise

Smoke inhalation is the major cause of death in fire victims due to cyanide poisoning. However, new research presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, shows that a new antidote, cobinamide, may help reverse the effects of cyanide toxicity.

Researchers from multiple institutions, including the University of California Irvine Medical Center, exposed six ventilator-supported New Zealand white rabbits to cold smoke breaths until toxic carbon monoxide levels were achieved, concurrent with intravenous cyanide infusion.

Intravenous cobinamide was administered in treatment arm animals and compared with control responses.

Results showed that intravenous cobinamide reversed cyanide toxicity in these animals in the face of smoke-induced carbon monoxide exposure, without evident adverse effects.

Researchers concluded that cobinamide shows promise as a potential antidote for in victims and that it could potentially be administered in mass casualty exposure scenarios.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Rapid response in cases of smoke poisoning

Sep 04, 2012

Smoke poisoning can be caused by a number of things, including cyanides, the salts of hydrocyanic acid. Because the quick diagnosis and treatment of victims with cyanide poisoning is critical and often lifesaving, ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

11 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

12 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

12 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

13 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments